Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

36.70USD
18 Aug 2017
Change (% chg)

$-0.17 (-0.46%)
Prev Close
$36.87
Open
$36.78
Day's High
$37.19
Day's Low
$36.50
Volume
372,853
Avg. Vol
626,327
52-wk High
$63.73
52-wk Low
$24.76

SRPT.OQ

Chart for SRPT.OQ

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $2,361.00
Shares Outstanding(Mil.): 64.33
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -2.44 -- --
ROI: -47.63 2.83 14.89
ROE: -49.74 5.09 16.13

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing

Aug 14 2017

BRIEF-Sarepta Therapeutics announces pricing of $325 mln public offering of common stock

* Sarepta Therapeutics announces pricing of $325 million public offering of common stock

Jul 24 2017

BRIEF-Sarepta Therapeutics announces proposed $250 mln public offering of common stock

* Sarepta Therapeutics announces proposed $250 million public offering of common stock

Jul 24 2017

Sarepta surges after stellar DMD drug powers on

Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.

Jul 20 2017

UPDATE 1-Sarepta surges after stellar DMD drug powers on

July 20 Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported much better-than-expected quarterly sales of its Duchenne muscular dystrophy (DMD) drug as the launch of the treatment steamrolls on.

Jul 20 2017

Sarepta surges after robust DMD drug sales

July 20 Shares of Sarepta Therapeutics Inc soared 25 percent on Thursday after the U.S. drugmaker reported strong quarterly sales of its drug to treat Duchenne muscular dystrophy (DMD).

Jul 20 2017

BRIEF-Sarepta Therapeutics and Clinigen launch managed access program

* Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with duchenne muscular dystrophy amenable to exon 51 skipping

Jul 19 2017

BRIEF-Sarepta Therapeutics secures $100 million in debt financing

* Sarepta Therapeutics secures $100 million in debt financing

Jul 18 2017

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

Jul 18 2017

Sarepta appoints former Allergan executive Douglas Ingram as CEO

Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer.

Jun 28 2017

Earnings vs. Estimates